GENOWAY SA (ALGEN.PA) Stock Fundamental Analysis

EPA:ALGEN • FR0004053510

2.46 EUR
-0.01 (-0.4%)
Last: Feb 23, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

4

Taking everything into account, ALGEN scores 4 out of 10 in our fundamental rating. ALGEN was compared to 77 industry peers in the Biotechnology industry. ALGEN has an average financial health and profitability rating. ALGEN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • In the past year ALGEN was profitable.
  • ALGEN had a negative operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: ALGEN reported negative net income in multiple years.
  • The reported operating cash flow has been mixed in the past 5 years: ALGEN reported negative operating cash flow in multiple years.
ALGEN.PA Yearly Net Income VS EBIT VS OCF VS FCFALGEN.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M 4M -4M

1.2 Ratios

  • ALGEN's Return On Assets of 3.31% is amongst the best of the industry. ALGEN outperforms 81.82% of its industry peers.
  • Looking at the Return On Equity, with a value of 7.00%, ALGEN belongs to the top of the industry, outperforming 81.82% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 3.17%, ALGEN is in the better half of the industry, outperforming 77.92% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for ALGEN is significantly below the industry average of 11.65%.
Industry RankSector Rank
ROA 3.31%
ROE 7%
ROIC 3.17%
ROA(3y)4.35%
ROA(5y)1.91%
ROE(3y)7.98%
ROE(5y)2.79%
ROIC(3y)5.56%
ROIC(5y)N/A
ALGEN.PA Yearly ROA, ROE, ROICALGEN.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20

1.3 Margins

  • Looking at the Profit Margin, with a value of 6.14%, ALGEN belongs to the top of the industry, outperforming 80.52% of the companies in the same industry.
  • ALGEN has a better Operating Margin (5.97%) than 77.92% of its industry peers.
  • The Gross Margin of ALGEN (94.91%) is better than 92.21% of its industry peers.
  • ALGEN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 5.97%
PM (TTM) 6.14%
GM 94.91%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.73%
GM growth 5Y0.4%
ALGEN.PA Yearly Profit, Operating, Gross MarginsALGEN.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ALGEN is destroying value.
  • ALGEN has less shares outstanding than it did 1 year ago.
  • The number of shares outstanding for ALGEN has been increased compared to 5 years ago.
  • Compared to 1 year ago, ALGEN has an improved debt to assets ratio.
ALGEN.PA Yearly Shares OutstandingALGEN.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
ALGEN.PA Yearly Total Debt VS Total AssetsALGEN.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

  • ALGEN has an Altman-Z score of 1.98. This is not the best score and indicates that ALGEN is in the grey zone with still only limited risk for bankruptcy at the moment.
  • The Altman-Z score of ALGEN (1.98) is better than 68.83% of its industry peers.
  • A Debt/Equity ratio of 0.71 indicates that ALGEN is somewhat dependend on debt financing.
  • ALGEN has a Debt to Equity ratio (0.71) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.71
Debt/FCF N/A
Altman-Z 1.98
ROIC/WACC0.42
WACC7.46%
ALGEN.PA Yearly LT Debt VS Equity VS FCFALGEN.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M 10M 15M

2.3 Liquidity

  • ALGEN has a Current Ratio of 2.41. This indicates that ALGEN is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of ALGEN (2.41) is comparable to the rest of the industry.
  • ALGEN has a Quick Ratio of 2.21. This indicates that ALGEN is financially healthy and has no problem in meeting its short term obligations.
  • With a Quick ratio value of 2.21, ALGEN perfoms like the industry average, outperforming 51.95% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.41
Quick Ratio 2.21
ALGEN.PA Yearly Current Assets VS Current LiabilitesALGEN.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • ALGEN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.46%.
  • Looking at the last year, ALGEN shows a decrease in Revenue. The Revenue has decreased by -2.21% in the last year.
  • The Revenue has been growing by 18.46% on average over the past years. This is quite good.
EPS 1Y (TTM)5.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.91%
Revenue 1Y (TTM)-2.21%
Revenue growth 3Y16.31%
Revenue growth 5Y18.46%
Sales Q2Q%-10.34%

3.2 Future

  • Based on estimates for the next years, ALGEN will show a decrease in Earnings Per Share. The EPS will decrease by 0.00% on average per year.
  • The Revenue is expected to grow by 10.37% on average over the next years. This is quite good.
EPS Next Y-100%
EPS Next 2Y-41.42%
EPS Next 3Y0%
EPS Next 5YN/A
Revenue Next Year-7.14%
Revenue Next 2Y3.51%
Revenue Next 3Y10.37%
Revenue Next 5YN/A

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ALGEN.PA Yearly Revenue VS EstimatesALGEN.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M
ALGEN.PA Yearly EPS VS EstimatesALGEN.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2023 2024 2027 0.05 0.1 0.15 0.2

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 16.40 indicates a correct valuation of ALGEN.
  • Compared to the rest of the industry, the Price/Earnings ratio of ALGEN indicates a rather cheap valuation: ALGEN is cheaper than 92.21% of the companies listed in the same industry.
  • The average S&P500 Price/Earnings ratio is at 26.64. ALGEN is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 16.4
Fwd PE N/A
ALGEN.PA Price Earnings VS Forward Price EarningsALGEN.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, ALGEN is valued cheaply inside the industry as 89.61% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 10.11
ALGEN.PA Per share dataALGEN.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.42%
EPS Next 3Y0%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ALGEN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GENOWAY SA

EPA:ALGEN (2/23/2026, 7:00:00 PM)

2.46

-0.01 (-0.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners5.68%
Inst Owner ChangeN/A
Ins Owners7.91%
Ins Owner ChangeN/A
Market Cap31.24M
Revenue(TTM)20.95M
Net Income(TTM)1.29M
Analysts86.67
Price Target6.02 (144.72%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 16.4
Fwd PE N/A
P/S 1.49
P/FCF N/A
P/OCF N/A
P/B 1.7
P/tB 2.52
EV/EBITDA 10.11
EPS(TTM)0.15
EY6.1%
EPS(NY)0
Fwd EYN/A
FCF(TTM)-0.82
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS1.65
BVpS1.45
TBVpS0.98
PEG (NY)N/A
PEG (5Y)N/A
Graham Number2.21
Profitability
Industry RankSector Rank
ROA 3.31%
ROE 7%
ROCE 3.94%
ROIC 3.17%
ROICexc 3.17%
ROICexgc 3.91%
OM 5.97%
PM (TTM) 6.14%
GM 94.91%
FCFM N/A
ROA(3y)4.35%
ROA(5y)1.91%
ROE(3y)7.98%
ROE(5y)2.79%
ROIC(3y)5.56%
ROIC(5y)N/A
ROICexc(3y)6.94%
ROICexc(5y)N/A
ROICexgc(3y)9.99%
ROICexgc(5y)N/A
ROCE(3y)6.91%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.73%
GM growth 5Y0.4%
F-Score3
Asset Turnover0.54
Health
Industry RankSector Rank
Debt/Equity 0.71
Debt/FCF N/A
Debt/EBITDA 2.88
Cap/Depr 297.91%
Cap/Sales 46.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.41
Quick Ratio 2.21
Altman-Z 1.98
F-Score3
WACC7.46%
ROIC/WACC0.42
Cap/Depr(3y)64.02%
Cap/Depr(5y)125.45%
Cap/Sales(3y)10.32%
Cap/Sales(5y)17.64%
Profit Quality(3y)100.54%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.91%
EPS Next Y-100%
EPS Next 2Y-41.42%
EPS Next 3Y0%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.21%
Revenue growth 3Y16.31%
Revenue growth 5Y18.46%
Sales Q2Q%-10.34%
Revenue Next Year-7.14%
Revenue Next 2Y3.51%
Revenue Next 3Y10.37%
Revenue Next 5YN/A
EBIT growth 1Y-28.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year200%
EBIT Next 3Y68.69%
EBIT Next 5YN/A
FCF growth 1Y-380.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.89%
OCF growth 3YN/A
OCF growth 5YN/A

GENOWAY SA / ALGEN.PA FAQ

Can you provide the ChartMill fundamental rating for GENOWAY SA?

ChartMill assigns a fundamental rating of 4 / 10 to ALGEN.PA.


What is the valuation status of GENOWAY SA (ALGEN.PA) stock?

ChartMill assigns a valuation rating of 2 / 10 to GENOWAY SA (ALGEN.PA). This can be considered as Overvalued.


What is the profitability of ALGEN stock?

GENOWAY SA (ALGEN.PA) has a profitability rating of 5 / 10.


Can you provide the PE and PB ratios for ALGEN stock?

The Price/Earnings (PE) ratio for GENOWAY SA (ALGEN.PA) is 16.4 and the Price/Book (PB) ratio is 1.7.


What is the financial health of GENOWAY SA (ALGEN.PA) stock?

The financial health rating of GENOWAY SA (ALGEN.PA) is 5 / 10.